{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:14:14Z","timestamp":1789456454560,"version":"build-2803163510"},"reference-count":8,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Talimogene laherparepvec (T\u2010VEC), an intralesional therapy designed to elicit an immunogenic anti\u2010tumor response, has a favorable safety profile in phase II trial and may be an effective second\u2010line therapeutic in sarcoma; however, there is a paucity of data on its therapeutic efficacy. We present a case series of patients who received T\u2010VEC for sarcoma at a high\u2010volume sarcoma center. A total of four patients who had prior progression of disease on immune checkpoint inhibitors (ICI) received a median of 9.5 (range, 4\u201315) doses of T\u2010VEC over 26.5 (range, 10\u201349) weeks with a median progression free\u2010survival of 9 weeks (range, 9\u201310). Only one patient experienced toxicity, which presented as mild flu\u2010like symptoms. This case series of patients receiving T\u2010VEC for sarcoma adds to the literature of intralesional therapies for this rare disease. Our experience suggests that T\u2010VEC may be administered safely and may provide local tumor control in select patients with sarcoma who have failed prior therapy with ICI.<\/jats:p>","DOI":"10.1002\/jso.70330","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T19:03:06Z","timestamp":1783882986000},"page":"505-507","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Talimogene Laherparepvec in Soft Tissue Sarcoma"],"prefix":"10.1002","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-7704","authenticated-orcid":false,"given":"Taylor P.","family":"Williams","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology The Ohio State University Medical Center Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Catalano","sequence":"additional","affiliation":[{"name":"School of Medicine The Ohio State University Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Liebner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology The Ohio State University Medical Center Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-0715","authenticated-orcid":false,"given":"Valerie P.","family":"Grignol","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology The Ohio State University Medical Center Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.10.005"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1116937"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6152"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.11570"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003119"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012446"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.70330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jso.70330","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.70330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:53:25Z","timestamp":1789455205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.70330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/jso.70330"],"URL":"https:\/\/doi.org\/10.1002\/jso.70330","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"2026-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}